跳到正文
原文
The Lancet Infectious Diseases· Nadine Rouphael, Shahida Baqar, Michelle Dickey, Christina Quigley, Tena Pham, Josh Adams, Gaurav Kwatra, Sarah Bechnak, Veronica Smith, Erin M Scherer, Daniel S Graciaa, Jill El-Khorazaty, Jamie A Fraser, Susan Heard, Krista Cato, Jorge Mejia-Galvis, Shoshana Barnoy, Lakshmi Chandrasekharan, Chad K Porter, Akamol E Suvarnapunya, Malabi M Venkatesan, Robert W Frenck, DMID 17-0112 Study Group·· 2026-07-01精选AI 评分77

WRSs2活疫苗在美国成人可控感染模型中预防志贺氏菌S sonnei痢疾的II期双盲随机对照试验

[Articles] Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial

AI 导读

在美国成人中进行的II期双盲随机安慰剂对照试验显示,活疫苗WRSs2对志贺氏菌S sonnei痢疾提供了高水平保护。虽然保护效果显著,但出现少数自限性3级不良事件,表明需进一步优化以明确安全性与疗效的平衡。这些结果支持继续推进活志贺氏菌疫苗的临床研发。

推荐理由

该II期随机双盲安慰剂对照试验在可控人体感染模型中评估了活 attenuated志贺氏菌S sonnei疫苗WRSs2的预防效果,为后续研发提供安全与疗效平衡数据。

来源:The Lancet Infectious Diseases · thelancet.com